eli lilly glp-1 advantage decreasing launches pill, kicking off showdown with Novo Nordisk Eli Lilly's oral GLP-1 pill

In: Bonora, E., DeFronzo, R

Across four JARDIANCE outcome trials, lower limb amputation event rates were 4.3 and 5.0 events per 1,000 patient-years in the placebo group and the JARDIANCE 10 mg or 25 mg dose group, respectively, with a HR of 1.05 (95 % CI) (0.81, 1.36)

Zang, L

Study endpoints include epithelial-barrier function, tight-junction protein expression, inflammatory signaling, and mucosal tissue remodeling in models of intestinal inflammation, increased permeability, and chemically induced gastrointestinal injury

The average time from diagnosis was only 4.3 years, shorter than the 6.4 years in the phase II trial and the 10-year period in the pilot study